The study of the range and sales volume of capillary stabilizing medicines presented at the domestic pharmaceutical market
DOI:
https://doi.org/10.24959/sphhcj.23.300Keywords:
pharmaceutical market analysis; manufacturing companies; sales; capillary stabilizing medicinesAbstract
Aim. To analyze the domestic pharmaceutical market and study the range of capillary stabilizing medicines for the period 2020-2023 by pharmacotherapeutic groups, manufacturing companies, dosage forms, etc.
Materials and methods. To conduct an analysis of the range of capillary stabilizing medicines, modern methods of analysis, in particular, generalization and systematization of information, as well as methods of mathematical and statistical calculations, were traditionally used.
The study object was information on the registration of medicines of the State Expert Center of the Ministry of Health of Ukraine, data from scientific publications. To substantiate the assessment of the capillary stabilizing medicines market and to determine the actual availability of drugs of the group studied, we analyzed the wholesale pharmaceutical market, in particular the offers of distribution companies. The data were obtained from the State Register of Medicines of Ukraine, the Compendium on-line and the research of the drug market “Proxima Research” of the analytical company “Morion” during 2020-2022 with the average offers of distributors by the group “Angioprotectors”, ATX code C05.
Results. Based on the results of the analysis of the registration data of medicines of the State Expert Center of the Ministry of Health of Ukraine, it has been determined that angioprotective agents belong to the C05C group according to the international АТС classification. As of September 1, 2023, 68 names of drugs of this group were registered in Ukraine by trade names, taking into account the dosage and package size. The domestic pharmaceutical market includes medicines of domestic production and 10 countries of foreign production, mainly the EU countries and Israel. According to the Register, 15 foreign and 15 domestic drug manufacturers currently supply angioprotective drugs to the pharmaceutical market. The results of the analysis indicate that the most of capillary stabilizing medicines presented at the domestic pharmaceutical market are drugs of Ukrainian production. Among domestic drugs with the angioprotective action, the lion’s share of the market belongs to the main three manufacturers – PJSC SIC “Borshchahivskiy CPP” covers 27 %, Arterium – 17 %, “Red Star” – 10 % of the total number of domestic drugs of this group. As for foreign-made medicines, their distribution by manufacturers is developing dynamically, taking into account the volumes of their sales both in physical and monetary terms. It has been proven that during 2020-2023, there is a tendency to increase the number of domestic drugs at the pharmaceutical market. In addition, we have found that for most of the assortment items in 2022, there is a significant decrease in the sales volumes of angioprotective drugs compared to previous periods.
Conclusions. According to the results of the study, the peculiarities of the range of capillary stabilizing medicines in Ukraine during 2020-2023 were determined, and during the study period, there was a tendency to increase the number of domestic drugs at the market and to reduce the overall level of consumption in 2022 compared to 2020-2021.
References
Angioprotektori. Farmacevtichna enciklopediya. Available at: https://www.pharmencyclopedia.com.ua/article/2784/angioprotektori.
Kovalenko V. M., Dorohoi A. P. (2016). Sertsevo-sudynni khvoroby: medychno-sotsialne znachennia ta stratehiia rozvytku kardiolohii v Ukraini. Ukrainskyi kardiolohichnyi zhurnal. Dod. 3, 5-14.
Sercevo-sudinni zahvoryuvannya. Klasifikatsiya, standarti diagnostiki ta likuvannya (2016). / Za red. V. M. Kovalenka, M. I. Lutaya, Yu. M. Sirenka, O. S. Sichova. 2-ge vid., pererobl. ta dopovn. Kyiv : MORION.
Nascimento, B. R., Brant, L. C., Moraes, D. N., Ribeiro, A. L. (2014). Global health and cardiovascular disease. Heart, 100, P. 1743–1749. doi:10.1136/heartjnl-2014-306026.
Blavacka, O. B., Zaliska, O. M., Grinkiv, Ya. O., Sosnovska, G. O. (2020). Analiz dinamiki rozvitku programi “Dostupni liki” v Ukrayini ta Lvivskij oblasti. Farmacevtichnij zhurnal. 75, 2, 3-11. doi:10.32352/0367-3057.2.20.01.
Balicka, O. P., Grigoruk, Yu. M., Gajdaj, O. D. (2019). Kompleksnij analiz priznachen likarskih zasobiv dlya likuvannya sercevo-sudinnih zahvoryuvan u stacionarnih umovah. Visnik farmaciyi. 2, (98), 36-40. doi:10.24959/nphj.19.6.
Five insights from the Global Burden of Disease Study 2019 (2020). The Lancet, 396, 10258. 1135-1159. https://www.sciencedirect.com/science/article/abs/pii/S0140673620314045
Kompendium – likarski preparati. Dovidnik likarskih zasobiv v Ukrayini No. 1. Available at: https:// compendium.com.ua/uk/atc/.
Programnij kompleks “Apteka” kompaniyi “Morion” Available at htts:// pharmbase.com.ua/poisk.
Derzhavnij reyestr likarskih zasobiv. Available at: http://www.drlz.com.ua/.
Nemchenko, A. S., Kuhtenko, O. S., Gladuh, Ye. V. (2017). Marketingovi doslidzhennya rinku likarskih zasobiv dlya likuvannya varikoznogo rozshirennya ven ta zapalnih zahvoryuvan suglobiv. Socialna farmaciya v ohoroni zdorov’ya, 3, 3. 66-73. doi:10.24959/sphhcj.17.87.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
